Deutsch English Français

Contact

EP2670765

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2670765

EP2670765 - C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 24.08.2018 Database last updated on 05.10.2024
Former	The patent has been granted Status updated on 15.09.2017
Former	Grant of patent is intended Status updated on 04.07.2017
Most recent event Tooltip	17.07.2020	Lapse of the patent in a contracting state New state(s): AL	published on 19.08.2020 [2020/34]
Applicant(s)	For all designated states VIIV HEALTHCARE UK (NO. 4) LIMITED 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[2017/41]
Former [2016/46]	For all designated states VIIV HEALTHCARE (NO. 4) LIMITED 980 Great West Road Brentford, Middlesex TW8 9GS / GB
Former [2013/50]	For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 05843-4000 / US
Inventor(s)	01 / REGUEIRO-REN, Alicia c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	02 / LIU, Zheng c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	03 / SWIDORSKI, Jacob c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	04 / SIN, Ny c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	05 / VENABLES, Brian Lee c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	06 / SIT, Sing-Yuen c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	07 / CHEN, Yan c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	08 / CHEN, Jie c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	09 / MEANWELL, Nicholas A. c/o Bristol-Myers Squibb Company 5 Research Parkway Wallingford, Connecticut 06492 / US
	[2013/50]
Representative(s)	Learoyd, Stephanie Anne, et al GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[2017/42]
Former [2013/50]	Reitstötter - Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
Application number, filing date	12702947.8	27.01.2012
	[2017/42]
	WO2012US22852
Priority number, date	US201161437893P	31.01.2011 Original published format: US 201161437893 P
	[2013/50]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2012106190
	Date:	09.08.2012
	Language:	EN
	[2012/32]
	Type:	A1 Application with search report
	No.:	EP2670765
	Date:	11.12.2013
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.08.2012 takes the place of the publication of the European patent application.
	[2013/50]
	Type:	B1 Patent specification
	No.:	EP2670765
	Date:	18.10.2017
	Language:	EN
	[2017/42]
Search report(s)	International search report - published on:	EP	09.08.2012
Classification	IPC:	C07J63/00, A61K31/56, A61P31/18	[2013/50]
	CPC:	A61K31/565 (EP,US); C07J63/00 (KR); A61K31/56 (EP,KR,US); A61K31/58 (EP,US); A61K31/704 (EP,US); A61K45/06 (US); (+) A61P31/12 (EP); A61P31/18 (EP); C07J63/008 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/50]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	C-17- C-3-MODIFIZIERTE TRITERPENOIDE MIT HIV-REIFUNGSHEMMENDER WIRKUNG	[2013/50]
	English:	C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY	[2013/50]
	French:	TRITERPÉNOÏDES MODIFIÉS EN C-17 ET C-3 PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE LA MATURATION DU VIH	[2013/50]
Entry into regional phase	20.08.2013	National basic fee paid
	20.08.2013	Designation fee(s) paid
	20.08.2013	Examination fee paid
Examination procedure	20.08.2013	Examination requested [2013/50]
	26.03.2014	Amendment by applicant (claims and/or description)
	18.03.2015	Despatch of a communication from the examining division (Time limit: M04)
	28.07.2015	Reply to a communication from the examining division
	05.07.2017	Communication of intention to grant the patent
	24.08.2017	Fee for grant paid
	24.08.2017	Fee for publishing/printing paid
	24.08.2017	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 18.03.2015
Opposition(s)	19.07.2018	No opposition filed within time limit [2018/39]
Fees paid	Renewal fee
	21.01.2014	Renewal fee patent year 03
	13.01.2015	Renewal fee patent year 04
	11.01.2016	Renewal fee patent year 05
	09.01.2017	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	27.01.2012
	AL	18.10.2017
	AT	18.10.2017
	CY	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	MK	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	TR	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	MT	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
	[2020/34]
Former [2020/31]	HU	27.01.2012
	AT	18.10.2017
	CY	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	MK	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	TR	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	MT	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2020/28]	HU	27.01.2012
	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	TR	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	MT	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2020/16]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	TR	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	MT	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2020/08]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	MT	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2019/30]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	MC	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2019/09]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IE	27.01.2018
	LU	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2018/52]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SI	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	LU	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2018/50]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	LU	27.01.2018
	BE	31.01.2018
	IS	18.02.2018
Former [2018/47]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	LU	27.01.2018
	IS	18.02.2018
Former [2018/40]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RO	18.10.2017
	RS	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IS	18.02.2018
Former [2018/37]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	PL	18.10.2017
	RS	18.10.2017
	SK	18.10.2017
	SM	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IS	18.02.2018
Former [2018/35]	AT	18.10.2017
	CZ	18.10.2017
	DK	18.10.2017
	EE	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	RS	18.10.2017
	SK	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IS	18.02.2018
Former [2018/24]	AT	18.10.2017
	FI	18.10.2017
	HR	18.10.2017
	LT	18.10.2017
	LV	18.10.2017
	RS	18.10.2017
	BG	18.01.2018
	NO	18.01.2018
	GR	19.01.2018
	IS	18.02.2018
Former [2018/22]	FI	18.10.2017
	LT	18.10.2017
	NO	18.01.2018
Cited in	International search	[A]WO2009100532 (VIROCHEM PHARMA INC [CA], et al) [A] 1-20 * the whole document, in particular pages 67-68, compounds 8-1, 9-1; pages 71-73, compounds 11-1, 12-1, 13-1, 13-2 * * page 99 - page 101; table 6 *;
		[YP]WO2011153315 (BRISTOL MYERS SQUIBB CO [US], et al) [YP] 1-20 * the whole document, in particular claims 1,11 and page 1, paragraph 1 *;
		[YP]WO2011153319 (BRISTOL MYERS SQUIBB CO [US], et al) [YP] 1-20* the whole document, in particular claims 1,11 and page 1, paragraph 1 *
	by applicant	US5413999
		US5679828
		WO0245652
		US2005209246
		US2005239748
		WO2006053255
		US7354924
		US7365221
		US2008207573
		WO2009058859
		WO2009100532
		WO2011007230
		- KASHIWADA, Y. ET AL., J. MED. CHEM., (1996), vol. 39, pages 1016 - 1017
		- POKROVSKII, A. G. ET AL., GOS. NAUCHNYI TSENTR VIRUSOL. BIOTEKHNOL, (2001), vol. 9, pages 485 - 491
		- DRUGS OF THE FUTURE, (1999), vol. 24, no. 12, pages 1355 - 1362
		- CELL, (19991029), vol. 9, pages 243 - 246
		- DRUG DISCOVERY TODAY, (200005), vol. 5, no. 5, pages 183 - 194
		- MEANWELL, NICHOLAS A.; KADOW, JOHN F., CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, (2003), vol. 6, no. 4, pages 451 - 461
		- J. AGUILERA ET AL., TETRAHEDRON ASYMMETRY, (2008), vol. 19, page 302

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p